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Abstract
The development of influenza candidate vaccine viruses (CVVs) for pre-pandemic vaccine 
production represents a critical step in pandemic preparedness. The multiple subtypes and clades 
of avian or swine origin influenza viruses circulating world-wide at any one time necessitates the 
continuous generation of CVVs to provide an advanced starting point should a novel zoonotic 
virus cross the species barrier and cause a pandemic. Furthermore, the evolution and diversity of 
novel influenza viruses that cause zoonotic infections requires ongoing monitoring and 
surveillance, and, when a lack of antigenic match between circulating viruses and available CVVs 
is identified, the production of new CVVs. Pandemic guidelines developed by the WHO Global 
Influenza Program govern the design and preparation of reverse genetics-derived CVVs, which 
must undergo numerous safety and quality tests prior to human use. Confirmation of reassortant 
CVV attenuation of virulence in ferrets relative to wild-type virus represents one of these critical 
steps, yet there is a paucity of information available regarding the relative degree of attenuation 
achieved by WHO-recommended CVVs developed against novel viruses with pandemic potential. 
To better understand the degree of CVV attenuation in the ferret model, we examined the relative 
virulence of six A/Puerto Rico/8/1934-based CVVs encompassing five different influenza A 
subtypes (H2N3, H5N1, H5N2, H5N8, and H7N9) compared with the respective wild-type virus 
in ferrets. Despite varied virulence of wild-type viruses in the ferret, all CVVs examined showed 
reductions in morbidity and viral shedding in upper respiratory tract tissues. Furthermore, unlike 
the wild-type counterparts, none of the CVVs spread to extrapulmonary tissues during the acute 
phase of infection. While the magnitude of virus attenuation varied between virus subtypes, 
collectively we show the reliable and reproducible attenuation of CVVs that have the A/Puerto 
Rico/9/1934 backbone in a mammalian model.
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1. Introduction
Influenza viruses cause seasonal epidemics and occasional pandemics in humans, with the 
severity of disease ranging from mild respiratory illness to acute respiratory disease and 
death. The continued circulation of influenza viruses in animal hosts represents a constant 
threat to human health should a virus jump the species barrier and cause human infection 
(Swayne, 2016); detection of novel influenza viruses in humans of avian and swine origin in 
recent years underscores that possibility (Uyeki et al., 2017). Vaccines represent the most 
effective public health tool to protect against influenza virus infection, but the prolonged 
lead time in vaccine virus development and manufacture make them difficult to employ in 
the early stages of a pandemic. In response, the WHO supports the generation of pre-
pandemic candidate vaccine viruses (CVVs); CVVs designated by the WHO currently 
encompass seven virus subtypes.
The ferret is the preferred mammalian model for the study of influenza virus pathogenesis 
and transmission, due to similarities in lung physiology, distribution of influenza virus 
receptors throughout the respiratory tract, and numerous shared clinical signs and symptoms 
of influenza virus infection (Belser et al., 2011). As such, pathogenicity and transmissibility 
data obtained from ferrets is included in the Influenza Risk Assessment Tool (IRAT), a 
multi-attribute model that supports decision-making efforts regarding the selection of 
appropriate candidate vaccine viruses (Cox et al., 2014). The WHO recommends the 
demonstration of attenuation of CVVs in ferrets prior to distribution to vaccine 
manufacturers (WHO, 2005b). While there have been several isolated studies showing CVV 
attenuation in ferrets (Dong et al., 2009; Robertson et al., 2011; Webby et al., 2004), no 
comprehensive analysis of the relative degree of attenuation among numerous strains/
subtypes of influenza viruses with pandemic potential has been reported. A better 
understanding of strain-specific variation compared with parameters uniformly present 
among all safety-tested viruses is critical when evaluating safety profiles of CVVs against 
influenza viruses with pandemic potential. This is of particular importance as demonstration 
that CVVs possess reduced pathogenicity is needed to Confirm the virus can be safely 
handled at the biosafety levels present during large-scale manufacturing of influenza 
vaccines. Similar to the current influenza vaccine production methods, the manufacturing 
process for CVVs includes virus concentration, inactivation, and purification procedures.
Here, we examined the mammalian virulence of six recently isolated wild-type influenza 
viruses from avian and swine reservoirs which have either been associated with human 
infection or are considered to pose a threat to human health, and determined the safety 
profile of each paired CVV using multiple parameters of the ferret model. Among ferrets 
inoculated with CVVs, we found strain-specific impacts of the HA and/or NA on morbidity 
and virus replication in the upper respiratory tract compared with the relevant wild-type 
virus, but high uniformity in the ablation of virus spread beyond the respiratory tract among 
all viruses analyzed. This study underscores the importance of aggregating safety-related in 
vivo data to demonstrate both the reliability and reproducibility of the A/Puerto Rico/8/1934 
(PR/8) based CVV safety profile in mammals and as a resource when new potentially 
pandemic viruses emerge.
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2. Methods
2.1. Viruses
Influenza A viruses included in the analyses in this study are listed in Table 1. All viruses 
were propagated in the allantoic cavity of 10–11 day old embryonated chicken eggs at 35–
37 °C for 24–48 h as described previously (Maines et al., 2009, 2005). Pooled allantoic fluid 
was clarified by centrifugation and aliquots were stored at −80 °C until use. Stock titers 
were titered for 50% egg infectious dose (EID50) or plaque forming units (PFU) in MDCK 
cells as described previously (Reed and Muench, 1938; Zeng et al., 2007). All experiments 
with avian-origin viruses were conducted under biosafety level 2 or 3 containment, including 
enhancements required by the U.S. Department of Agriculture and the Division of Select 
Agents and Toxins/CDC (Chosewood et al., 2009).
Reassortant vaccine candidate viruses (GLP candidate vaccine viruses) were generated by 
transfecting reverse genetics plasmids encoding the HA and NA surface gene segments of 
the virus of interest along with reverse genetics constructs encoding the PB2, PB1, PA, NP, 
M, and NS gene segments of PR/8 influenza virus (plasmids described in Ridenour et al. 
(2015a)) into certified Vero cells (O’Neill and Donis, 2009). HA and NA Genbank accession 
numbers: EU258939, EU258937 (RG27); JN401974, CY062485 (RG29); CY103897, 
CY098760 (RG30); KF021597.1, KF021599.1 (RG32A); KP307984.1, KP307986.1 
(RG43A). In some cases, HA and NA genes may be synthetically produced based on genetic 
sequence information (Dormitzer, 2015). For hemagglutinin gene segments of highly 
pathogenic avian H5N1 influenza viruses, constructs were generated that delete the region 
coding for polybasic amino acids juxtaposed to the HA1/HA2 protease cleavage site to 
create a mono-basic amino acid cleavage site characteristic of low pathogenic viruses (Dong 
et al., 2009; O’Neill and Donis, 2009; Subbarao et al., 2003; World Health Organization 
Global Influenza Program Surveillance, 2005). Automated sequencing was performed using 
an Applied Biosystems 3130 genetic analyzer to Confirm both a matching genetic sequence 
with the parental viruses, and to verify the lack of a polybasic sequence at the HA cleavage 
site. Sterility testing of each CVV for bacterial (aerobic, anaerobic) and fungal contaminates 
was performed (WHO, 2005b).
2.2. Ferret experiments
Male Fitch ferrets (Triple F Farms, Sayre, PA), 6–12 months of age and serologically 
negative by hemagglutination inhibition assay to currently circulating influenza viruses, 
were used in this study. Animal research was conducted under the guidance of the Centers 
for Disease Control and Prevention’s Institutional Animal Care and Use Committee in an 
Association for Assessment and Accreditation of Laboratory Animal Care International-
accredited animal facility. Ferrets were housed for the duration of each experiment in a Duo-
Flo BioClean environmental enclosure (Lab Products, Seaford, DE). For each virus tested, 6 
ferrets were intranasally (i.n.) inoculated with 106 PFU or EID50 of virus diluted in PBS in a 
1 ml volume. Wild-type ferret pathotyping data was published previously as indicated by the 
references provided in Table 1. In all experiments, three ferrets were monitored daily for 
clinical signs and symptoms of infection for 14 days, with nasal wash (NW) samples 
collected on alternate days post-inoculation (p.i.) for virus titration in eggs or cells as 
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previously described (Maines et al., 2005). Any ferret that lost > 25% of its pre-inoculation 
body weight or displayed signs of neurological dysfunction was euthanized. Three 
additional ferrets were euthanized day 3 p.i. for collection and titration of systemic tissues as 
previously described (Maines et al., 2005). Statistical significance of NW viral titers 
between CVV and wild-type strains was determined by Student’s t-test.
3. Results
3.1. Generation and validation of candidate vaccine viruses
The generation of reassortant viruses was performed according to WHO guidance for 
development of vaccine reference viruses (WHO, 2005b) (Fig. 1). Briefly, the hemagglutinin 
(HA) and neuraminidase (NA) genes were amplified from viral RNA either extracted from 
the donor virus, or generated synthetically, using Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR). Amplified PCR products for HA and NA genes were ligated into the 
transcription plasmid, Confirmed by sequence analysis, and co-transfected together with the 
six internal gene plasmids from PR/8, to produce recombinant virus. Recombinant virus 
containing HA and NA from the donor virus on a PR/8 backbone were propagated in 
specific pathogen free (SPF) 10–11 day-old embryonated chicken eggs for at least two 
passages.
Following propagation in eggs, all candidate vaccine viruses underwent further testing to 
assess phenotype and pathogenicity. This included chicken embryo lethality testing to verify 
reduced pathogenicity of reassortant viruses, and for viruses derived from an HA donor virus 
with a highly pathogenic sequence at the HA cleavage site, chicken pathogenicity testing 
and a trypsin-dependent plaque assay (OIE, 2015). These assays verified reduced 
pathogenicity of reassortant viruses (data not shown). Upon successful completion of all 
safety and quality testing, viruses are eligible to become a candidate vaccine virus (CVV), 
and may be designated as such by WHO (2016a, 2017).
3.2. Virulence of candidate vaccine viruses in ferrets
According to WHO recommendations, CVV attenuation must be demonstrated in the ferret 
model, including reductions in viral titer of the CVV compared with the wild-type strain in 
respiratory tract tissues and an absence of extrapulmonary spread (WHO, 2005a, 2013), as 
ferrets typically function as a reliable indicator of influenza virus virulence in humans 
(Belser et al., 2011; Smith and Sweet, 1988). To examine the degree of attenuation that the 
HA modifications and PR/8 backbone typically provide, we compared the relative virulence 
of each CVV to the wild-type parental virus or a genetically related wild-type strain. The 
wild-type viruses included in this study possessed a range of virulence in ferrets: the H2N3, 
H5N1, and H7N9 viruses exhibited moderate virulence (mean maximum weight loss 6.5–
13.7%, with one dk/VN/12 virus-inoculated ferret succumbing to disease day 7 p.i.), while 
the HPAI H5N2 and H5N8 viruses exhibited low virulence (mean maximum weight loss < 
4%) (Table 1). Mean maximum rises in body temperature ranging from 1.3 to 1.9 °C above 
baseline pre-inoculation readings were observed among wild-type viruses independent of 
virulence characterization.
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Severe disease and lethality were not detected in any ferret inoculated with a CVV. All 
CVVs exhibited reductions in mean maximum weight loss in ferrets compared to wild-type 
virus infection, with the magnitude of weight loss reduction dependent on the severity of the 
wild-type virus. H2N3, H5N1 (Egypt), and H7N9 CVVs exhibited the most pronounced 
reduction in morbidity in ferrets (ranging from 7.8% to 9.5% reductions in weight loss from 
pre-inoculation body weight compared with wild-type infection), while H5N1 (Hubei), 
H5N2, and H5N8 viruses exhibited less overall effect on morbidity (0.2–2.7% reductions in 
weight loss from pre-inoculation body weight compared with wild-type infection) (Table 1). 
All ferrets inoculated with H2 or H5 subtype CVVs exhibited reductions in peak mean rise 
in body temperature post-inoculation compared with wild-type virus infection, ranging from 
modest reductions (0.2–0.4 °C reductions for H2N3 and H5N2 subtype viruses) to more 
pronounced reductions (0.8–1.1 °C reductions for H5N1 and H5N8 subtype viruses). These 
data indicate that the relative virulence of CVV strains must be compared with wild-type 
strains to fully appreciate the degree of attenuation achieved by the vaccine strain.
3.3. Attenuated replication of CVVs in the ferret upper respiratory tract
The reverse genetics PR/8 virus does not cause severe disease in ferrets, but is capable of 
moderate replication in the ferret upper respiratory tract through day 5 p.i. (Dong et al., 
2009). To determine the kinetics and magnitude of CVV replication in the ferret upper 
respiratory tract, nasal wash (NW) samples from ferrets inoculated with wild-type or CVVs 
were collected on alternate days 1–9 p.i. and titered for the presence of infectious virus (Fig. 
2). In agreement with morbidity measurements (Table 1), the wild-type viruses in this study 
exhibited a range of titers, with the H2N3 and H7N9 wild-type viruses replicating to highest 
titer in this sample (reaching peak mean titers > 106 EID50/ml or PFU/ml day 1 p.i.) and the 
H5N8 virus replicating with least efficiency (peak mean titers < 103.1 EID50/ml day 1 p.i.). 
Independent of peak NW titers reached in this sample, virus was cleared by day 9 p.i. in all 
virus-inoculated ferrets.
When compared with the wild-type viruses, all CVVs exhibited reductions in virus shedding 
in NW samples. The greatest attenuation was observed among H5N1 CVVs compared with 
wild-type counterpart viruses, which had significantly reduced titers detected on days 1–5 
p.i. in NW samples among all CVV strains (p < 0.05, Fig. 2). H2N3 and H7N9 expressing 
CVVs also had significantly reduced viral titers in NW samples, reaching peak fold 
reductions in viral load of > 1000-fold and > 100-fold on days 1 and 5 p.i., respectively. The 
H5N8 CVV replicated so inefficiently that it was not detected (limit of detection 1.5 log10 
EID50/ml) in NW specimens of any inoculated ferret during the acute phase of infection. 
Reductions in viral titer in NW samples between wild-type and CVV for H5N2 and H5N8 
subtypes were not statistically significant, likely due to poor fitness among wild-type strains 
in ferrets. With the exception of H2N3 virus, all other CVVs tested further possessed 
reduced viral loads in ferret nasal turbinates collected day 3 p.i., providing an additional 
measure of reduction of virus replication in the nasal cavity (Fig. 3). Collectively, reduced 
viral titers were present in the upper respiratory tract following infection with CVVs 
compared with wild-type viruses, but the relative degree of viral load reduction was subtype-
specific and likely influenced by the robustness of replication of the wild-type strain.
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3.4. Ablated systemic spread of CVVs in ferrets
Unlike human seasonal influenza viruses which are typically restricted to replication in the 
ferret upper respiratory tract, influenza viruses which are associated with severe disease in 
ferrets are typically detected at high titer in the lower respiratory tract and recovered from 
extrapulmonary tissues, including the brain (Maines et al., 2005). In agreement with most 
zoonotic influenza viruses examined in the ferret model, all wild-type influenza viruses in 
this study were detected in the trachea and lung day 3 p.i. (Fig. 3). Furthermore, all H5 and 
H7 wild-type influenza viruses were detected in the olfactory bulb of the brain, and two 
viruses (Egypt H5N1 and H7N9) were detected in both anterior and posterior regions of the 
brain at this time p.i. Viral isolation from intestinal tissue was detected only with HPAI 
H5N1 (Egypt) and H5N8 viruses (Pearce et al., 2016; Pulit-Penaloza et al., 2015).
In contrast with wild-type strains, CVVs were detected more sporadically and to lower titer 
than homologous wild-type virus in the lower respiratory tract tissues (Fig. 3). Virus was 
recovered in the trachea of 3/6 CVV-inoculated ferrets (H2N3, H7N9) and the lung of 4/9 
CVV-inoculated ferrets (H2N3, H7N9, H5N2), but in all instances both the mean titer and 
incidence of detection were reduced compared with the wild-type counterpart. No infectious 
virus was detected in the olfactory bulb, brain, or intestine of any CVV-inoculated ferret. 
These findings indicate that CVVs were attenuated in both their dissemination to lower 
respiratory tract tissues and as well as to extrapulmonary tissues in the ferret model on day 3 
p.i.
4. Discussion
While circulating seasonal human influenza A viruses are restricted to a few subtypes 
(Azziz-Baumgartner et al., 2015), there are multiple subtypes of zoonotic influenza viruses 
that have extensive strain-specific variation circulating throughout the world (WHO, 2016b). 
These viruses can sometimes adapt between hosts, accelerating the acquisition of mutations 
that can potentially lead to wider within host transmission (Ridenour et al., 2015b). The 
development of CVVs against zoonotic viruses and subsequent vaccine products for the 
assessment of vaccine immunogenicity, optimal vaccination strategies and/or stockpiling are 
important pandemic preparedness efforts (WHO, 2006). However, the strain-specific 
phenotypic/genotypic variation of these viruses requires the development of a specific 
vaccine against an actual pandemic virus. Despite these challenges, the creation of a bank of 
CVVs antigenically matched to the currently circulating potentially pandemic strains 
enables a rapid and more informed response for emergency use.
The attenuation of the pathogenicity of the potential CVV must be shown before its 
inclusion in any list of WHO candidate vaccine viruses for use in a pandemic (WHO-GISN, 
2011). Attenuation of pathogenicity of the candidate vaccine virus in both chicken embryos 
and 4–7 week old chickens are required indicators for vaccine virus environmental biosafety. 
Additionally, chicken pathogenicity testing is performed on all viruses that are derived from 
highly-pathogenic avian influenza parental strains. Sequencing of both wild-type and 
candidate vaccine viruses were performed to verify the lack of a highly pathogenic genotype 
in the candidate vaccine virus, and to Confirm an absence of mutations in the surface genes 
that might lead to a loss of antigenicity. Parallel work that can occur further downstream of 
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the safety testing of the CVV involves analysis of HA yield and further improvements in 
growth characteristics necessary for large-scale expansion and stockpiling. Specifically, 
alternate PR/8 internal gene segments with different characteristics can be combined with 
the HA and NA from the CVV in order to optimize yield through different gene segment 
interactions (Johnson et al., 2015). In addition, further passaging in eggs is another approach 
to elicit egg-adapted changes that can improve yield while maintaining antigenicity 
similarity to parental virus (Ridenour et al., 2015a).
A few studies have reported the attenuation of CVVs in the ferret model in comparison to 
wild-type strains, but rarely have provided specific data regarding the degree of attenuation 
(Dong et al., 2009; Robertson et al., 2011; Webby et al., 2004). Our results highlight that the 
relative degree of attenuation of CVVs is strain-specific, and dependent on the properties of 
the parental virus. CVVs exhibited varied reductions in morbidity (as measured by weight 
loss), fever, magnitude and duration of virus shedding in upper respiratory tract tissues, as 
well as presence of detectable virus in lower respiratory tract tissues. While all CVVs 
included in this study possessed an attenuated phenotype compared with wild-type viruses in 
the ferret model, the alignment of numerous CVVs of different virus subtypes and lineages 
included here underscores the need to assess numerous parameters when determining an 
attenuated phenotype in a mammalian model. Furthermore, a poorly studied component of 
virus attenuation is reduction in transmissibility. Although determination of transmission 
efficiency is not required to confirm CVV attenuation (WHO, 2005b), we performed a 
transmission experiment in ferrets for one CVV, RG27 (H2N3) and found that the H2N3 
CVV failed to transmit by respiratory droplets, whereas the wild-type (sw/MO/06) virus 
transmitted to 66% of naïve contacts ((Pappas et al., 2015) and data not shown).
In all CVVs examined in this study, the degree of attenuation in the ferret model was relative 
to the virulence of the wild-type strain, again illustrating the impact the HA and NA play in 
pathogenesis. In ferrets, H2N3 and H7N9 CVVs exhibited peak mean viral titers in nasal 
wash samples > 105 EID50 or PFU/ml, which is higher than any wild-type H5N1 strain 
included in this study; both H2N3 and H7N9 viruses possess an enhanced capacity to bind to 
α2–6 linked sialic acid receptors, which may confer a fitness advantage in the ferret model 
compared with avian-like H5N1 viruses (Fig. 2) (Pappas et al., 2015; Xiong et al., 2013). 
Nonetheless, H2N3 and H7N9 CVVs showed reduced virulence compared with wild-type 
strains, as demonstrated by diminished morbidity and reduced viral replication in the upper 
and lower respiratory tract. Similarly, the range of peak viral titers throughout the respiratory 
tract of ferrets inoculated with H5 subtype viruses, and the absence or presence of 
extrapulmonary virus spread among H5-inoculated ferrets, aids in the interpretation of 
attenuation observed among HPAI H5 subtype CVVs. Collectively, these results underscore 
the value of paired wild-type control pathotyping data when assessing CVV attenuation 
while simultaneously demonstrating the achievement of virus attenuation of CVV strains 
regardless of wild-type strain virulence in this mammalian model.
Ferrets are studied to assess the attenuation of influenza countermeasures relative to wild-
type virus infection. In addition to CVVs for inactivated vaccines, ferrets are used to assess 
the safety of live attenuated influenza vaccine viruses (Shcherbik et al., 2015; Shen et al., 
2016; Zhou et al., 2010), and examination of the protective effects of prior infection with 
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heterologous viruses (Houser et al., 2013), among other vaccine approaches against both 
influenza and other viruses of public health concern (Enkirch and von Messling, 2015). 
These studies also vary in the degree of attenuation afforded but collectively highlight the 
utility of ferrets in evaluating the pre-clinical effectiveness of influenza countermeasures to 
mitigate clinical signs and symptoms of infection, magnitude and dissemination of virus 
replication, and in some instances, transmissibility. The continued development of ferret-
specific reagents will improve our understanding of vaccine immunogenicity in this model, 
and will further enable a role for ferrets in the continued development of universal influenza 
vaccines (Margine and Krammer, 2014).
The creation of CVVs represents a pillar of public health pandemic preparedness. The WHO 
guidelines ensure a reliably safe, attenuated, non-pathogenic virus strain appropriate for 
large-scale manufacturing facilities. Our results further reinforce the reliability and 
reproducibility of reverse-genetics CVVs engineered as PR/8-based 6:2 reassortants with a 
range of viruses with pandemic potential. This study addressed the attenuation of CVVs 
developed against multiple zoonotic influenza viruses which pose a threat to human health. 
However, there remains a need to assess the ability of vaccines developed using these CVVs, 
including stockpiled vaccines, to elicit protective antibodies against continually evolving and 
increasingly antigenically diverse influenza viruses with pandemic potential (Pearce et al., 
2011).
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Fig. 1. Generation, validation, and safety testing of candidate vaccine viruses
Influenza virus reassortant candidate vaccine viruses (CVVs) were created according to 
WHO guidance for development of vaccine reference viruses (WHO, 2005b). Methodology 
is described in detail in Sections 2 and 3.
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Fig. 2. Mean nasal wash viral titer of wild-type and CVVs in ferrets
Three ferrets per group were inoculated with 106 PFU or EID50 of virus (grey bars, wild-
type virus; black bars, CVV). Nasal washes were collected on alternate days p.i. Mean titers 
for each group are shown as log10 EID50/ml + standard deviation (SD) with the exception of 
H7N9 viruses which are shown as log10 PFU/ml. The limit of detection was 1.5 log10 
EID50/ml or 1 log10 PFU/ml. *, p < 0.05 between wild-type and CVV groups.
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Fig. 3. Systemic replication of wild-type and CVVs in ferrets
Three ferrets per group were inoculated with 106 PFU or EID50 of virus (grey bars, wild-
type virus; black bars, CVV), and tissues were collected 3 days p.i. for virus titration. Mean 
titers for each group are shown as log10 EID50/g or ml + SD with the exception of H7N9 
viruses which are shown as log10 PFU/g or ml. All titers are reffective of virus detection in 
3/3 ferrets unless specified otherwise. NT, nasal turbinates; Tr, trachea; Lg, lung; BnOB, 
olfactory bulb; BnA, anterior brain; BnP, posterior brain; Int, intestine (pooled). The limit of 
detection was 1.5 log10 EID50/g or ml or 1 log10 PFU/g or ml (all samples are expressed per 
g with the exception of NT, which is expressed per ml).
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